Skip to content

Homepage

from science to hope.

Our mission

Opening new frontiers in brain health.

HOPE Study

HOPE was our large-scale study to test how our science could help people with mild-to-moderate Alzheimer’s preserve the everyday abilities they depend on.

Learn more

The results could help preserve the everyday abilities that matter most.

82%

Slowing of decline in function
(ADCS-ADL)

Results shown apply to early symptomatic AD over 12 months.
Per protocol adherence population.*

The What Matters Most Framework.

To understand what the HOPE findings could mean for people and families, we translated clinical results into everyday life. The What Matters Most framework, created by leading Alzheimer’s advocacy organizations, helped us show the HOPE findings through the everyday abilities people value most.

Daily Activities.

Everyday tasks help us stay independent and connected to the people around us.

Communication.

Preserving communication keeps us in the conversation.

Social Life.

Spending time with others helps us stay connected, share experiences and feel part of life.

General Independence.

Being able to make choices and do things for ourselves helps us live on our own terms.

Thought Processing.

Thinking clearly lets us trust our own minds.

The Science Behind the Study
The Science Behind the Study

Working with the brain’s own biology.

Spectris is Cognito’s scientific platform, designed to synchronize brain activity.

The HOPE Study examined whether this approach could have the potential to preserve cognition, function and the abilities we depend on to think, remember, connect, and participate in everyday life for people with mild-to-moderate Alzheimer’s.

Learn more

Spectris is Cognito’s scientific platform, designed to synchronize brain activity.

The HOPE Study examined whether this approach could have the potential to preserve cognition, function and the abilities we depend on to think, remember, connect, and participate in everyday life for people with mild-to-moderate Alzheimer’s.

Our story
Our story

Cognito began from groundbreaking neuroscience research at MIT.

Learn more
Where next?
Where next?

Beginning with Alzheimer’s, we’re working towards better brain health for everyone.

Learn more

Your next step with Cognito starts here.

Tell us what you’re looking for and we’ll help you find the right information or people.

*The per-protocol group includes participants who used Spectris for at least 6 months, completed a full one-hour session on at least 5 days a week on average, and followed the main study rules.

Sabbagh MN, Kern RZ, Zusterzeel R, Hamilton RH. Spectris Treatment in Mild-to-Moderate Alzheimer’s Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study. Presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference; November 16-19, 2026; Boston, Massachusetts.